$1.510
0.000 (0.00%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Transcode Therapeutics Inc (RNAZ) Moving Averages Convergence Divergence (MACD) indicator is -0.09, suggesting RNAZ is Strong sell.
Transcode Therapeutics Inc (RNAZ) 20-Day simple moving average is 1.67, while Transcode Therapeutics Inc (RNAZ) share price is $—, making it Sell.
Transcode Therapeutics Inc (RNAZ) 60-Day simple moving average is 1.92, while Transcode Therapeutics Inc (RNAZ) share price is $—, making it Sell.
Technical Analysis for RNAZ
AI Technical RNAZAs of 2026-11-07, the technical board for Transcode Therapeutics Inc (RNAZ) reads strong sell: 2 indicators are flashing buy, 9 are indicating sell, and 2 are neutral. Price at $1.51 sits below every tracked moving average (5-day, 10-day, 20-day, 60-day and 200-day).
Momentum readings: RSI stands at 35.253, MACD stands at -0.093 (Sell), Stochastic %K stands at 13.711 (Buy), Stochastic %D stands at 15.672 and CCI stands at -218.968 (Buy).
RNAZ trades below the 60-day SMA (1.92) and below the 200-day SMA (5.96). Immediate resistance sits at Classic R1 1.88, then R2 2.12. Support sits at Classic S1 1.42, then S2 1.20.
Transcode Therapeutics Inc (RNAZ) Support & Resistance Level
Transcode Therapeutics Inc (RNAZ) Technical Indicators
2026-11-07
| Name | Value |
|---|---|
| RSI_14 | 35.253 |
| STOCHk_14_3_3 | 13.711 |
| STOCHd_14_3_3 | 15.672 |
| CCI_20 | -218.968 |
| AO_5_34 | -0.126 |
| MOM_10 | -0.280 |
| MACD_12_26_9 | -0.093 |
Transcode Therapeutics Inc (RNAZ) Relative Strength Index (RSI_14) is 35.253, creating a Neutral signal.
Transcode Therapeutics Inc (RNAZ) Stochastic %K is 13.711, creating a Buy signal.
Transcode Therapeutics Inc (RNAZ) Stochastic %D is 15.672, creating a Buy signal.
Transcode Therapeutics Inc (RNAZ) CCI_20 is -218.968, creating a Buy signal.
Transcode Therapeutics Inc (RNAZ) Awesome Oscillator (AO) is -0.126, creating a Sell signal.
Transcode Therapeutics Inc (RNAZ) Momentum (MOM) is -0.280, creating a Sell signal.
Transcode Therapeutics Inc (RNAZ) Moving Average Convergence Divergence (MACD) is -0.093, creating a Sell signal.
Transcode Therapeutics Inc (RNAZ) Moving Average
2026-11-07
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 1.560 | Sell |
| MA_10 | 1.628 | Sell |
| MA_20 | 1.667 | Sell |
| MA_60 | 1.923 | Sell |
| MA_200 | 5.959 | Sell |
| MA_250 | 6.459 | Sell |
Transcode Therapeutics Inc (RNAZ) 5-Day simple moving average is 1.560, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Transcode Therapeutics Inc (RNAZ) 10-Day simple moving average is 1.628, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Transcode Therapeutics Inc (RNAZ) 20-Day simple moving average is 1.667, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Transcode Therapeutics Inc (RNAZ) 60-Day simple moving average is 1.923, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Transcode Therapeutics Inc (RNAZ) 200-Day simple moving average is 5.959, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Transcode Therapeutics Inc (RNAZ) 250-Day simple moving average is 6.459, while Transcode Therapeutics Inc (RNAZ) share price is $, making it a Sell.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.